Literature DB >> 3278591

Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease.

B Schorr-Lesnick1, L J Brandt.   

Abstract

This review focuses on the behavior and pathogenesis of selected dermatologic and rheumatologic manifestations of inflammatory bowel disease. Erythema nodosum, the most common skin lesion, correlates with activity of the bowel disease but not with its duration or extent. Resolution occurs with therapy of inflammatory bowel disease. Pyoderma gangrenosum, the most severe skin lesion, bears little relationship to the activity or extent of the colitis. Therapy is usually supportive, but dapsone and steroids appear promising. Immune and vasculitic mechanisms have been postulated for both skin lesions. Peripheral arthritis usually has its onset with or after the development of colitic symptoms. It worsens with exacerbation of bowel inflammation and responds to treatment of the bowel disease. Immune mechanisms are likely. Spondyloarthropathy usually occurs before the onset of overt intestinal disease. Its course is unrelated to the bowel inflammation, it does not respond to treatment of bowel disease, and it is associated with HLA B27.

Entities:  

Mesh:

Year:  1988        PMID: 3278591

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Peripheral arthritis in the course of inflammatory bowel diseases.

Authors:  Ilhami Yüksel; Hilmi Ataseven; Omer Başar; Seyfettin Köklü; Ibrahim Ertuğrul; Aysel Ulker; Ulkü Dağlı; Nurgül Saşmaz
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

2.  Extraintestinal manifestations of inflammatory bowel disease.

Authors:  Jonathan S Levine; Robert Burakoff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

3.  Refractory, disfiguring vulvar pyoderma gangrenosum and Crohn's disease.

Authors:  M L Borum; M Cannava; C Myrie-Williams
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 4.  Important cutaneous manifestations of inflammatory bowel disease.

Authors:  L B Trost; J K McDonnell
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

5.  The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease.

Authors:  Nuran Turkcapar; Murat Toruner; Irfan Soykan; Olcay Tiryaki Aydintug; Hulya Cetinkaya; Nursen Duzgun; Ali Ozden; Murat Duman
Journal:  Rheumatol Int       Date:  2005-09-01       Impact factor: 2.631

6.  [Initial symptoms, extra-intestinal manifestations and course of pregnancy in chronic inflammatory bowel diseases].

Authors:  H C Rath; T Andus; I Caesar; J Schölmerich
Journal:  Med Klin (Munich)       Date:  1998-07-15

7.  Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease.

Authors:  Patrick Danoy; Karena Pryce; Johanna Hadler; Linda A Bradbury; Claire Farrar; Jennifer Pointon; Michael Ward; Michael Weisman; John D Reveille; B Paul Wordsworth; Millicent A Stone; Walter P Maksymowych; Proton Rahman; Dafna Gladman; Robert D Inman; Matthew A Brown
Journal:  PLoS Genet       Date:  2010-12-02       Impact factor: 5.917

Review 8.  Gastrointestinal lesions associated with spondyloarthropathies.

Authors:  Ambrogio Orlando; Sara Renna; Giovanni Perricone; Mario Cottone
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

Review 9.  Systemic lupus erythematosus complicated by Crohn's disease: a case report and literature review.

Authors:  Hiroyuki Yamashita; Yo Ueda; Hoshimi Kawaguchi; Akitake Suzuki; Yuko Takahashi; Hiroshi Kaneko; Toshikazu Kano; Akio Mimori
Journal:  BMC Gastroenterol       Date:  2012-12-05       Impact factor: 3.067

10.  Dietary therapy with Lactobacillus GG, bovine colostrum or bovine immune colostrum in patients with juvenile chronic arthritis: evaluation of effect on gut defence mechanisms.

Authors:  M Malin; P Verronen; H Korhonen; E L Syväoja; S Salminen; H Mykkänen; H Arvilommi; E Eerola; E Isolauri
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 5.093

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.